Differential survival benefit of universal HAART access in Brazil: A nation-wide comparison of injecting drug users versus men who have sex with men

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 629-635

  Malta, Monica ^a   Bastos, Francisco I ^a   Da Silva, Cosme M F P ^a   Pereira, Gerson Fernando Mendes ^b   Lucena, Francisca F A ^b   Fonseca, Maria G P ^c   Strathdee, Steffanie A ^d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b MINISTÉRIO DA SAÚDE   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Drug user; HAART; HIV; Survival

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG USE; ETHNIC DIFFERENCE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD; ADOLESCENT; COMPARATIVE STUDY; DEVELOPING COUNTRY; FACTUAL DATABASE; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; RISK FACTOR; SUBSTANCE ABUSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DATABASES, FACTUAL; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 73349127513     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b31b8a     Document Type: Article

References (48)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
2. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
3. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
4. Levine RS, Briggs NC, Kilbourne BS, et al. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health. 2007;97:1884-1892.
5. Harper S, Lynch J. Highly active antiretroviral therapy and socioeconomic inequalities in AIDS mortality in Spain. Eur J Public Health. 2007;17: 231.
6. Dray-Spira R, Gueguen A, Ravaud JF, et al. Socioeconomic differences in the impact of HIV infection on workforce participation in France in the era of highly active antiretroviral therapy. Am J Public Health. 2007;97: 552-558.
7. Braga P, Cardoso MR, Segurado AC. Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS. 2007;21:321-328.
8. Hacker MA, Petersen ML, Enriquez M, et al. Highly active antiretroviral therapy in Brazil: the challenge of universal access in a context of social inequality. Rev Panam Salud Publica. 2004;16:78-83.
9. Kiguba R, Byakika-Tusiime J, Karamagi C, et al. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr. 2007;45:218-223.
10. 9 cells/L. Ann Intern Med. 2003;139:810-816.
11. Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 2003;17:711-720.
12. Fein O. The influence of social class on health status. American and British research on health inequalities. J Gen Intern Med. 1995;10: 577-586.
13. Aceijas C, Oppenheimer E, Stimson GV, et al. Antiretroviral treatment for injecting DU in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction. 2006;101:1246-1253.
14. Palepu A, Tyndall M, Yip B, et al. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32:522-526.
15. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection DU. AIDS. 2001;15: 1707-1715.
16. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115-1123.
17. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004;190: 1046-1054.
18. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study. J Acquir Immune Defic Syndr. 1999;21:114-119.
19. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
20. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection DU: adherence, resistance, and death. Cad Saude Publica. 2006; 22:705-718.
21. Malta M, Strathdee SA, Magnanini MM, et al. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103: 1242-1257.
22. Malta M, Magnanini MM, Strathdee SA, et al. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2008;1-17.
23. Bastos FI, Kerrigan D, Malta M, et al. Treatment for HIV/AIDS in Brazil: strengths, challenges, and opportunities for operations research. AIDScience. 2001;1. Available at: http://aidscience.org/Articles/aidscience012.asp. Accessed November 12, 2008. [serial online].
24. Simao M. Drug pricing policies and challenges: lessons from Brazil [THSY0102]. Presented at: XVII International AIDS Conference; August 2-8, 2008, Mexico City, Mexico.
25. Nunn AS, Fonseca EM, Bastos FI, et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med. 2007;4:e305.
26. Melo AC, Caiaffa WT, Cesar CC, et al. Utilization of HIV/AIDS treatment services: comparing injecting drug users and other clients. Cad Saude Publica. 2006;22:803-813.
27. Camargo KR Jr, Coeli CM. Reclink: an application for database linkage implementing the probabilistic record linkage method. Cad Saude Publica. 2000;16:439-447.
28. Cook LJ, Olson LM, Dean JM. Probabilistic record linkage: relationships between file sizes, identifiers and match weights. Methods Inf Med. 2001; 40:196-203.
29. Grannis SJ, Overhage JM, Hui S, et al. Analysis of a probabilistic record linkage technique without human review. AMIA Annu Symp Proc. 2003; 2003:259-263.
30. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-241.
31. Clayton DG. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika. 1978;65:141-151.
32. Hougaard P. Analysis of Multivariate Survival Data. New York, NY: Springer; 2000.
33. Aalen OO. Effects of frailty in survival analysis. Stat Methods Med Res. 1994;3:227-243.
34. Carvalho MS, Andreozzi VL, Codexco CT, et al. Survival Analysis: Theory and Health Applications. [In Portuguese]. Rio de Janeiro, Brazil: Editora Fiocruz; 2005.
35. Naskar M, Das K, Ibrahim JG. A semiparametric mixture model for analyzing clustered competing risks data. Biometrics. 2005;61:729-737.
36. R Core Development Team [computer software] Version 2.8.0. Vienna, Austria: R Foundation for Statistical Computing; 2004.
37. Rodŕiguez-Arenas MA, Jarrín I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2006; 22:715-723.
38. Blades R, Li K, Kerr T, et al. Contribution of HIV to mortality among injection drug users in the era of HAART. J Acquir Immune Defic Syndr. 2007;46:655-656. (Pubitemid 350191061)
39. Kirk GD, Vlahov D. Improving survival among HIV-infected injection drug users: how should we define success? Clin Infect Dis. 2007;45: 377-380.
40. Marins JR, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17:1675-1682.
41. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749.
42. Pérez-Hoyos S, del Amo J, Muga R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS. 2003;17:353-359.
43. Cardoso MN, Caiaffa WT, Mingoti SA, and Projeto AjUDE-Brasil II. AIDS incidence and mortality in injecting drug users: the AjUDE-Brasil II. Project. Cad Saude Publica. 2006;22:827-837.
44. Wood E, Kerr T, Hogg RS, et al. Impact of HIV testing on uptake of HIV therapy among antiretroviral näive HIV-infected injection drug users. Drug Alcohol Rev. 2006;25:451-454.
45. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active anti-retroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47:712-722.
46. Lima VD, Gill VS, Yip B, et al. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis. 2008;198:51-58.
47. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
48. Pádua CA, César CC, Bonolo PF, et al. High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res. 2006;39:495-505.